Douglas L. Jennings, PharmD, FACC, FAHA, FCCP, FHFSA, BCPS

Talking Therapeutics

Entering 2023 With Hope for Targeted Therapies

01/05/2023

Douglas L. Jennings , PharmD, FACC, FAHA, FCCP, FHFSA, BCPS;

Dr Jennings discusses new agents for hypertrophic obstructive cardiomyopathy and Alzheimer disease that are intended to treat underlying disease mechanisms rather than symptoms.

Dr Jennings discusses new agents...

01/05/2023

Pharmacy Learning Network

Talking Therapeutics

Targeting Triglycerides to Treat Residual CV Risk

08/04/2021

Douglas L. Jennings , PharmD, FACC, FAHA, FCCP, FHFSA, BCPS;

Dr Jennings discusses updated guidelines for the treatment of hypertriglyceridemia, recently published by the American College of Cardiology and American Heart Association, in this week’s Talking Therapeutics.

Dr Jennings discusses updated...

08/04/2021

Pharmacy Learning Network

Talking Therapeutics

COVID-19 Vaccines: Time to Boost Yet Again?

03/31/2022

Douglas L. Jennings , PharmD, FACC, FAHA, FCCP, FHFSA, BCPS;

In the latest installment of Talking Therapeutics, Dr Jennings explores administering a fourth COVID-19 vaccine dose in light of new research on the second booster's efficacy.

In the latest installment of...

03/31/2022

Pharmacy Learning Network

Talking Therapeutics

What’s the Deal With Xenotransplantation?

11/04/2022

Douglas L. Jennings , PharmD, FACC, FAHA, FCCP, FHFSA, BCPS;

Dr Jennings discusses the potential of xenotransplantation, the transplant of nonhuman tissues and organs into a human recipient, for alleviating organ scarcity across the world.

Dr Jennings discusses the...

11/04/2022

Pharmacy Learning Network

Talking Therapeutics

A Watershed Moment for Weight Loss

11/22/2023

Douglas L. Jennings , PharmD, FACC, FAHA, FCCP, FHFSA, BCPS;

In this week's issue, Dr Jennings discusses the rates of obesity and how GLP-1 agonists may be vital in treating patients with obesity who have cardiovascular disease.

In this week's issue, Dr...

11/22/2023

Pharmacy Learning Network

Talking Therapeutics

Finding New Pillars of Care for HFpEF

10/07/2024

Douglas L. Jennings , PharmD, FACC, FAHA, FCCP, FHFSA, BCPS;

In this installment of Talking Therapeutics, we explore whether the novel medication finerenone, which has a demonstrated benefit in patients with kidney disease, can also improve outcomes in patients with HFpEF.

In this installment of Talking...

10/07/2024

Pharmacy Learning Network

Talking Therapeutics

Are all SGLT2 Inhibitors Created Equal?

07/19/2024

Douglas L. Jennings , PharmD, FACC, FAHA, FCCP, FHFSA, BCPS;

In this installment of Talking Therapeutics, Dr Jennings explores a new study that evaluates dapagliflozin against empagliflozin in patients with heart failure.

In this installment of Talking...

07/19/2024

Pharmacy Learning Network